Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAle… Read more
Nymox Pharmaceutical Corporation (NYMXF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.283x
Based on the latest financial reports, Nymox Pharmaceutical Corporation (NYMXF) has a cash flow conversion efficiency ratio of 0.283x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-897.00K) by net assets ($-3.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nymox Pharmaceutical Corporation - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Nymox Pharmaceutical Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nymox Pharmaceutical Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nymox Pharmaceutical Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yoshiharu Global Co.
NASDAQ:YOSH
|
-0.192x |
|
Enthusiast Gaming Holdings Inc.
PINK:EGLXF
|
-0.170x |
|
Sietel Ltd
AU:SSL
|
-0.001x |
|
Montebalito S.A.
MC:MTB
|
0.013x |
|
Scandium Interna
TO:SCY
|
-0.069x |
|
KCI SA
WAR:KCI
|
0.002x |
|
TGS Esports Inc
V:TGS
|
0.391x |
|
SUPERNOVA METALS CORP.
F:A1S
|
N/A |
Annual Cash Flow Conversion Efficiency for Nymox Pharmaceutical Corporation (2019–2023)
The table below shows the annual cash flow conversion efficiency of Nymox Pharmaceutical Corporation from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-3.17 Million | $-4.06 Million | 1.279x | -88.16% |
| 2022-12-31 | $-482.00K | $-5.21 Million | 10.799x | +109.13% |
| 2021-12-31 | $83.00K | $-9.82 Million | -118.313x | -3122.76% |
| 2020-12-31 | $2.73 Million | $-10.04 Million | -3.671x | -99.47% |
| 2019-12-31 | $4.04 Million | $-7.43 Million | -1.840x | -- |